Collagen supplements eased knee osteoarthritis pain across 11 trials

Knee osteoarthritis is one of the most common causes of joint pain and lost mobility, and many people managing it would prefer options beyond long-term painkillers. Collagen is a structural protein central to cartilage, and oral collagen supplements have been sold for joint health for years, with individual trials producing results of varying strength. Whether swallowing collagen actually translates into less pain and better knee function has remained a live question. This updated review set out to pool the randomised evidence and establish where the balance currently lies.

The authors searched four major medical databases, MEDLINE, EMBASE, Web of Science and Scopus, up to October 2023 for randomised controlled trials testing oral collagen-based supplements in people with knee osteoarthritis. Eleven trials qualified, contributing 870 participants in total, of whom 451 were allocated to collagen supplementation and 419 to placebo. Results were pooled statistically, with the pooling method chosen according to how much the trials varied from each other, and the risk of bias in each trial was assessed with the Cochrane Risk of Bias 2.0 tool. The outcomes were scores of knee function and pain.

Collagen supplementation came out ahead on both outcomes. Function scores improved by 6.46 points more than placebo on average, and pain scores improved by 13.63 points more, both statistically significant. The authors describe these improvements as noteworthy clinically as well as statistically, which matters because a change can reach statistical significance while being too small for a person to notice. The main weakness is that the trials disagreed with each other considerably on the size of the effect, particularly for pain, so the pooled averages carry real uncertainty even though the direction of benefit was consistent.

Collagen has often been filed alongside supplements with more marketing than evidence, so a pooled analysis of eleven randomised trials finding consistent benefit against placebo is a meaningful data point. As an update of earlier reviews, it strengthens an existing case rather than opening a new one. Open questions remain: the review pooled collagen-based supplements as a group, so it cannot say which preparations, doses or durations work best, nor how collagen compares with established osteoarthritis treatments rather than placebo. The disagreement between trials also means the true size of the benefit is not yet pinned down.

If you have painful knees and have eyed collagen supplements sceptically, this is a reason to take the category a little more seriously: across the pooled trials, people taking collagen reported less pain and better function than those taking placebo, by margins the authors judge clinically relevant. It is not proof that any particular product will help, and the variation between trials suggests individual results differ. Nothing here identifies a dose, a brand or a type of collagen. Treat it as evidence worth knowing about when weighing options, not a prompt to buy anything.